Retosiban

Retosiban

Retosiban is a drug that is classified as an oxytocin receptor antagonist. It was developed by GlaxoSmithKline for the management of preterm labor.

History

Retosiban was first synthesized by GlaxoSmithKline in the early 21st century. The drug was developed as a potential treatment for preterm labor, a condition that affects approximately 10% of all pregnancies worldwide.

Mechanism of Action

Retosiban works by blocking the action of oxytocin, a hormone that stimulates uterine contractions. By inhibiting the oxytocin receptor, Retosiban can potentially delay or prevent the onset of labor.

Clinical Trials

Several clinical trials have been conducted to evaluate the safety and efficacy of Retosiban. In Phase II trials, the drug was found to be well-tolerated and showed promising results in delaying preterm labor. However, further studies are needed to confirm these findings and to determine the optimal dosing regimen.

Potential Applications

In addition to its potential use in preterm labor, Retosiban may also have applications in other conditions that involve oxytocin, such as postpartum hemorrhage, dysmenorrhea, and certain psychiatric disorders.

See Also

• Oxytocin receptor antagonist
• Preterm labor
• Clinical trials
• GlaxoSmithKline

This article is a stub related to pharmacology. You can help WikiMD by expanding it!